Ivars C. Cintins

Array ( [id] => 19692906 [patent_doc_number] => 20250011451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => FUSION PROTEINS FOR IMMUNOTHERAPY AGAINST CANCER AND INFECTIOUS DISEASES [patent_app_type] => utility [patent_app_number] => 18/826183 [patent_app_country] => US [patent_app_date] => 2024-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18826183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20686627 [patent_doc_number] => 12616756 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-05 [patent_title] => Dimeric antibodies [patent_app_type] => utility [patent_app_number] => 18/807087 [patent_app_country] => US [patent_app_date] => 2024-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 11749 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 578 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18807087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526642 [patent_doc_number] => 20240350544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => COMPOSITIONS TARGETING BCMA AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/640982 [patent_app_country] => US [patent_app_date] => 2024-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380935 [patent_doc_number] => 20240270805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/588643 [patent_app_country] => US [patent_app_date] => 2024-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464206 [patent_doc_number] => 20240317875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF INFLAMMATORY CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/588587 [patent_app_country] => US [patent_app_date] => 2024-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31592 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359297 [patent_doc_number] => 20240261331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASES [patent_app_type] => utility [patent_app_number] => 18/429758 [patent_app_country] => US [patent_app_date] => 2024-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20438686 [patent_doc_number] => 12509513 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Anti-L1CAM antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 18/407065 [patent_app_country] => US [patent_app_date] => 2024-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 33045 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18407065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389474 [patent_doc_number] => 20240279344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => MAGE-A4 PEPTIDE-MHC ANTIGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 18/404536 [patent_app_country] => US [patent_app_date] => 2024-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38340 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18404536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034198 [patent_doc_number] => 20240084013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => Use of Combination of Anti-PD-1 Antibody and VEGFR Inhibitor in Preparation of Drug for Treating Cancers [patent_app_type] => utility [patent_app_number] => 18/517345 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263734 [patent_doc_number] => 20240207431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER [patent_app_type] => utility [patent_app_number] => 18/511857 [patent_app_country] => US [patent_app_date] => 2023-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8561 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172480 [patent_doc_number] => 20240158454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/492141 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18492141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111318 [patent_doc_number] => 20240123068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => CD19 BINDERS, CAR-T CONSTRUCTS COMPRISING THE SAME, AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/381215 [patent_app_country] => US [patent_app_date] => 2023-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71513 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18381215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020144 [patent_doc_number] => 20240076315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => KHL POLYPEPTIDE, AND USE THEREOF IN PREPARATION OF TABP-EIC CELL [patent_app_type] => utility [patent_app_number] => 18/380834 [patent_app_country] => US [patent_app_date] => 2023-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18380834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112839 [patent_doc_number] => 20240124589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => METHODS OF TREATING UROTHELIAL CARCINOMA USING AN ANTI-PD-1 ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/473858 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18473858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065713 [patent_doc_number] => 20240100139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => NEOANTIGENS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/462026 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18462026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032580 [patent_doc_number] => 20240082395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => Anti-SIRP-Alpha Antibodies and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 18/454286 [patent_app_country] => US [patent_app_date] => 2023-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18454286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018972 [patent_doc_number] => 20240075143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => CD7-TARGETED ENGINEERED IMMUNE CELL, CHIMERIC ANTIGEN RECEPTOR, CD7 BLOCKING MOLECULE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/351466 [patent_app_country] => US [patent_app_date] => 2023-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18351466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19043609 [patent_doc_number] => 11932693 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Monoclonal antibodies directed against programmed death-1 protein and their use in medicine [patent_app_type] => utility [patent_app_number] => 18/315686 [patent_app_country] => US [patent_app_date] => 2023-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 62643 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 319 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18315686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537546 [patent_doc_number] => 20230242644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMA [patent_app_type] => utility [patent_app_number] => 18/109281 [patent_app_country] => US [patent_app_date] => 2023-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18109281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691040 [patent_doc_number] => 20230321231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/061227 [patent_app_country] => US [patent_app_date] => 2022-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18061227 [rel_patent_id] =>[rel_patent_doc_number] =>)